A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.

@article{Olsen1996ADP,
  title={A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.},
  author={Nancy J Olsen and Rebecca H Brooks and John J. Cush and Peter E Lipsky and Eugene William St. Clair and Eric L Matteson and Kenneth N. Gold and Grant Cannon and Christopher G. Jackson and William J. Mccune and David A Fox and Betty Nelson and Tobias Lorenz and Vibeke Strand},
  journal={Arthritis and rheumatism},
  year={1996},
  volume={39 7},
  pages={1102-8}
}
OBJECTIVE To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). METHODS A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CD5-IC. RESULTS Treatment with CD5-IC in doses up to 8 mg/m2/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
11 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…